Please assess the completion status of the following clinical trial:

Trial Title: Saline Hypertonic in Preschoolers + CT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of CF as evidenced by one or more clinical features consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:~   1. A documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis (QPIT)~  2. A documented genotype with two disease-causing mutations in the CFTR gene~2. Informed consent by parent or legal guardian~3. Age ≥ 36 months and ≤72 months at screening visit~4. Ability to comply with medication use, study visits and study procedures as judged by the site investigator~5. Ability to cooperate with chest CT at the enrollment visit as determined by the lung function technician~Exclusion Criteria:~1. Chest CT within 8 months prior to the Screening visit~2. Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset within 3 weeks preceding screening or enrollment visit~3. Acute wheezing at screening or enrollment visit~4. Oxygen saturation \< 95% (\<90% in centers located above 4000 feet elevation) at screening or enrollment visit~5. Other major organ dysfunction, excluding pancreatic dysfunction~6. Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator~7. Investigational drug use within 30 days prior to screening or enrollment visit~8. Treatment with inhaled HS at any concentration within 30 days prior to screening or enrollment visit~9. Initiation (i.e. new prescription) of any inhaled hydrating agent such as mannitol or mucolytic agents such as dornase alpha within 30 days prior to the screening or enrollment visit~10. Chronic lung disease not related to CF~11. Inability to tolerate first dose of study treatment at the enrollment visit

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Active Treatment Group (Type: EXPERIMENTAL): 7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
- Control Group (Type: ACTIVE_COMPARATOR): 0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).